Linked e-resources
Details
Table of Contents
Dedication; Foreword; Preface; Contents; Contributors; Chapter 1: Comorbidity in Rheumatic Diseases; Cardiovascular Disease in Rheumatic Disease; Epidemiology; Pathophysiology; Risk Factors; Assessment and Prediction; CV Risk Management; Infection in Rheumatic Diseases; Site-Specific Infections; Corticosteroids and Risk of Infection; Key Recommendations for Clinical Practice; Malignancy in Rheumatic Diseases; Malignancy and Systemic Lupus Erythematous; Malignancy and Rheumatoid Arthritis; Malignancy and Systemic Sclerosis; Malignancy and Inflammatory Myopathies
Malignancy and Sjögren's Syndrome DMARDs and Malignancy; Rheumatic Disease and Osteoporosis; Insulin Resistance and Rheumatic Diseases; Interstitial Lung Diseases in Rheumatic Diseases; Anemia in Rheumatic Diseases; Comorbidity Pattern, Effect on Outcomes, and Recommendations for Clinical Practice; References; Chapter 2: Impact of Comorbidity; Comorbidity in Rheumatic Diseases; Prevalence; Multidimensional Impact of Comorbidity; Impact on Prescribing Medications; Financial Impact; Impact on Clinical Research; Effect of Comorbidity on Mortality
Effect of Comorbidity on Physical Function Comorbidity and Disease Outcomes; Medical Guidelines and Comorbidities; Management of Comorbidities; Screening; Conclusion; References; Chapter 3: Rheumatoid Arthritis; Cardiovascular Disease; Pericardial Disease; Ischaemic Heart Disease; Cardiomyopathy; Congestive Cardiac Failure; Valve Disease; Arrhythmia Including QT Effects of Drugs; Hypertension; Stroke and Peripheral Vascular Disease; Thromboembolic Disease; Respiratory Disease; Interstitial Lung Disease; Subtypes of ILD; Treatment of ILD in RA
Treatment Considerations in ILD Airways Disease; Bronchiectasis; Pleural Disease; Pulmonary Nodules; Malignancy; Cancers and Rheumatoid Arthritis; Solid Cancers; Skin Cancers; Lymphoma; Monitoring for Malignancy and Routine Care; Management of Patients Who Develop Malignancy During Treatment; Infections; Nonbiologic DMARDs and Infections; Biologics and Infections; Viral Hepatitis and Rheumatoid Arthritis; HIV and Rheumatoid Arthritis; Rheumatoid Vasculitis; Secondary MSK Disease; Osteoporosis; Osteoarthritis; Fibromyalgia; Psychological Comorbidity; Depression; Anxiety
Psychosis Impact of Comorbidities in RA; Assessment and Management of Comorbidities in RA; Conclusion; References; Chapter 4: Psoriasis; Inflammatory Pathway: "The Psoriatic March" from Gene to Clinic; Psoriatic Arthritis; Background and Pathophysiology; Science-Based Medicine; Therapeutic Implications; Inflammatory Bowel Disease; Background and Pathophysiology; Science-Based Medicine; Therapeutic Implications; Obesity; Background and Pathophysiology; Science-Based Medicine; Therapeutic Implications; Diabetes Mellitus/Insulin Resistance; Background and Pathophysiology
Malignancy and Sjögren's Syndrome DMARDs and Malignancy; Rheumatic Disease and Osteoporosis; Insulin Resistance and Rheumatic Diseases; Interstitial Lung Diseases in Rheumatic Diseases; Anemia in Rheumatic Diseases; Comorbidity Pattern, Effect on Outcomes, and Recommendations for Clinical Practice; References; Chapter 2: Impact of Comorbidity; Comorbidity in Rheumatic Diseases; Prevalence; Multidimensional Impact of Comorbidity; Impact on Prescribing Medications; Financial Impact; Impact on Clinical Research; Effect of Comorbidity on Mortality
Effect of Comorbidity on Physical Function Comorbidity and Disease Outcomes; Medical Guidelines and Comorbidities; Management of Comorbidities; Screening; Conclusion; References; Chapter 3: Rheumatoid Arthritis; Cardiovascular Disease; Pericardial Disease; Ischaemic Heart Disease; Cardiomyopathy; Congestive Cardiac Failure; Valve Disease; Arrhythmia Including QT Effects of Drugs; Hypertension; Stroke and Peripheral Vascular Disease; Thromboembolic Disease; Respiratory Disease; Interstitial Lung Disease; Subtypes of ILD; Treatment of ILD in RA
Treatment Considerations in ILD Airways Disease; Bronchiectasis; Pleural Disease; Pulmonary Nodules; Malignancy; Cancers and Rheumatoid Arthritis; Solid Cancers; Skin Cancers; Lymphoma; Monitoring for Malignancy and Routine Care; Management of Patients Who Develop Malignancy During Treatment; Infections; Nonbiologic DMARDs and Infections; Biologics and Infections; Viral Hepatitis and Rheumatoid Arthritis; HIV and Rheumatoid Arthritis; Rheumatoid Vasculitis; Secondary MSK Disease; Osteoporosis; Osteoarthritis; Fibromyalgia; Psychological Comorbidity; Depression; Anxiety
Psychosis Impact of Comorbidities in RA; Assessment and Management of Comorbidities in RA; Conclusion; References; Chapter 4: Psoriasis; Inflammatory Pathway: "The Psoriatic March" from Gene to Clinic; Psoriatic Arthritis; Background and Pathophysiology; Science-Based Medicine; Therapeutic Implications; Inflammatory Bowel Disease; Background and Pathophysiology; Science-Based Medicine; Therapeutic Implications; Obesity; Background and Pathophysiology; Science-Based Medicine; Therapeutic Implications; Diabetes Mellitus/Insulin Resistance; Background and Pathophysiology